Company intelligence / Profile preview
Dendright
Brisbane, Queensland, Australiadendright.com.au ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Dendright developed a nanoparticle-based immunotherapy platform (Curcusome) targeting autoimmune diseases. Its lead candidate, DEN-181, was designed to induce immune tolerance in rheumatoid arthritis by delivering disease-specific antigens and a VDR agonist. Early clinical trials showed some success, but the main program is currently suspended and there are no active late-stage programs.
- Therapeutic areas
- EndocrinologyImmunology
- Modalities
- NanoparticleBiologic
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Janssen Biotech, Inc. (collaboration on rheumatoid arthritis immunotherapy development)
Beyond the preview
Go deeper on Dendright.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dendright.